ライフサイエンスコーパス: biodistribution

1 ( approximately 20 MBq for PET, 5-7 MBq for biodistribution).

2 4)Cu(II) was observed through PET images and biodistribution.

3 of human were calculated based on the mouse biodistribution.

4 h after injection, organs were harvested for biodistribution.

5 teristics, including enzymatic stability and biodistribution.

6 biological barriers that limit their optimal biodistribution.

7 ) in nonhuman primates, including whole-body biodistribution.

8 determine acute toxicity, tumorigenicity and biodistribution.

9 showed extended blood retention and improved biodistribution.

10 rug release in physiological conditions, and biodistribution.

11 s of uptake outside the expected physiologic biodistribution.

12 major organs after systemic circulation and biodistribution.

13 , T(1/2)=5.6days), allow the imaging of this biodistribution.

14 y coupled plasma mass spectrometry to assess biodistribution.

15 uired for 90 min, followed by gamma-counting biodistribution.

16 as a model tracer dye to facilitate study of biodistribution.

17 umor derived from SPECT/CT (102 Gy) and from biodistribution (110 Gy) agreed to within 6.9%.

18 Tissue biodistribution (7 d after tracer administration, 1.11 M

19 Biodistribution analyses suggested AAV vectors persisted

20 xt developed this technique for quantitative biodistribution analysis in vivo.

21 Biodistribution analysis revealed an initial temporary e

22 Biodistribution analysis showed that the BTNP facilitate

23 The aim of this study was to investigate biodistribution and absorbed doses to organs at risk.

24 We assessed the impact of these features on biodistribution and antiviral efficacy in vitro and in v

25 Biodistribution and autoradiographic studies were perfor

26 nockout and wildtype rats as well as in vivo biodistribution and brain PET imaging studies in wildtyp

27 that are therefore expected to have a single biodistribution and cytotoxicity.

28 he present phase I study was to evaluate the biodistribution and dosimetry of (18)F-FAZA in non-small

29 oth imaging methods faithfully monitored the biodistribution and elimination routes of the compounds,

30 ective of this research was to determine the biodistribution and estimate the radiation dose from (68

31 e aim of the present work was to measure the biodistribution and estimate the radiation dosimetry of

32 ay be decomposed into different parts, whose biodistribution and fate would need to be analyzed indiv

33 Conclusion:(68)Ga-OPS202 showed favorable biodistribution and imaging properties, with optimal tum

34 tide amount of (177)Lu-NeoBOMB1, after which biodistribution and imaging studies were performed.

35 (18)F-FCP was evaluated using ex vivo biodistribution and in vivo PET imaging in non-tumor-bea

36 )Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic pr

37 Purpose To evaluate the normal biodistribution and kinetics of (S)-4-(3-[18F]fluoroprop

38 (18)F-MFBG imaging is safe and has favorable biodistribution and kinetics with good targeting of lesi

39 rapidly release PTX, resulting in widespread biodistribution and low tumor exposure.

40 The in vivo biodistribution and metabolism of complex 13 and its (99

41 female or male mice are used, differences in biodistribution and nonspecific tissue uptake can advers

42 gy has broad applicability for improving the biodistribution and performance of particulate delivery

43 -tissue ratios were observed both in ex vivo biodistribution and PET for comparably large doses, for

44 The biodistribution and PET studies after intravenous and su

45 Biodistribution and PET/CT examinations were performed f

46 Both mice and rats showed similar biodistribution and pharmacokinetics of (89)Zr-Df-pembro

47 Analyses of SNA biodistribution and pharmacokinetics revealed rapid intr

48 The use of formulations to regulate biodistribution and promote antigen and inflammatory cue

49 The biodistribution and radiation dosimetry were assessed by

50 Biodistribution and radiometabolite studies were perform

51 t immune responses, resulting in undesirable biodistribution and short blood residence time.

52 In vivo biodistribution and small-animal PET imaging were perfor

53 Biodistribution and small-animal SPECT/CT imaging (18.5

54 Biodistribution and small-animal SPECT/CT imaging studie

55 aptation of tools to rapidly quantitate cell biodistribution and survival after delivery.

56 y, we also review the current status of MPhi biodistribution and survival after transplantation into

57 The favorable tracer biodistribution and the first-in-human results will make

58 The self-assembly feature enhances biodistribution and the half-life of the peptides, while

59 Biodistribution and thrombus detection was investigated

60 imaging was performed to visualize (18)F-FLT biodistribution and to determine pharmacokinetics.

61 ical compositions of NPs caused inconsistent biodistribution and toxic profiles which attracted littl

62 Herein we investigate in vivo biodistribution and toxicity of intravesically instilled

63 tion played a critical role in their in vivo biodistribution and toxicity.

64 We aimed to gain insight into MSB0010853 biodistribution and tumor uptake by radiolabeling the Na

65 Biodistribution and tumor uptake of (89)Zr-AMG 110 was s

66 Normal-organ biodistribution and tumor uptake were quantified using S

67 The biodistribution and tumoral SUVs for both tracers were c

68 The biodistribution and uptake of three (18)F-labeled leucin

69 isotopologues of lorlatinib to determine the biodistribution and whole-body dosimetry assessments by

70 The accumulation, biodistribution, and clearance profiles of therapeutic a

71 e, we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-trastuzumab.

72 is study, we evaluated the pharmacokinetics, biodistribution, and dosimetry of pembrolizumab in vivo,

73 PET imaging, biodistribution, and dosimetry studies in mice, as well

74 Tumor uptake, biodistribution, and dosimetry studies were performed to

75 The primary aims were assessment of safety, biodistribution, and dosimetry.

76 s were performed to assess pharmacokinetics, biodistribution, and dosimetry.

77 rformed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry.

78 This review discusses the integrity, biodistribution, and fate of NPs after in vivo administr

79 me, reduced renal clearance, increased tumor biodistribution, and greater silencing of luciferase com

80 We report the safety, biodistribution, and internal radiation dosimetry, in hu

81 The tumor uptake, biodistribution, and pharmacokinetics were not significa

82 (18)F-FETrp tumoral uptake, biodistribution, and radiation dosimetry data provide st

83 purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for t

84 -human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging wi

85 irst-in-human (11)C-metformin PET dosimetry, biodistribution, and tissue kinetics study.

86 y, which suggested improved tumor targeting (biodistribution) as the most likely mechanism of AR160 t

87 Ex vivo biodistribution assays were performed to quantify the ac

88 Biodistribution at 7 d after administration of [(89)Zr]Z

89 PET imaging, biodistribution, autoradiography and immunohistochemistr

90 The results from biodistribution, autoradiography, and microPET imaging s

91 Herein, we focus on the effects on biodistribution based on modulating electronic influenci

92 xploits the signal intensity, stability, and biodistribution behavior of submicron-diameter molecular

93 The differential pattern of (18)F-FLT biodistribution between the sexes seen with (18)F-FLT wa

94 ed nuclear and optical imaging agents and by biodistribution, blocking, and ex vivo molecular charact

95 Additionally, ex vivo biodistribution, blocking, and histological studies were

96 e pool of particles, and quantified particle biodistribution by deep sequencing the barcodes.

97 nges in drug delivery to macrophages such as biodistribution, cellular uptake, intracellular traffick

98 or (64)Cu-LLP2A were extrapolated from mouse biodistribution data (6 time points, 0.78 MBq/animal, n=

99 Post-SPECT biodistribution data also validated the SPECT imaging re

100 ses to tumors and organs were estimated from biodistribution data and summed for the fractions.

101 Ex vivo biodistribution data confirmed high and persistent uptak

102 Ex vivo biodistribution data confirmed the accuracy of the PET r

103 l analysis was applied to recently published biodistribution data of immuno-PET imaging with (64)Cu-c

104 Using the favorable biodistribution data of the NTR1-targeting agent (111)In

105 Biodistribution data showed the highest tissue accumulat

106 ocess, involving expression level (Bmax) and biodistribution determination, a PET-specific structure-

107 Uptake outside the expected physiologic biodistribution did not significantly differ between (68

108 Given these promising findings, biodistribution, dosimetry, and brain kinetic modeling o

109 ith neuroendocrine tumors (NETs) to evaluate biodistribution, dosimetry, and safety.

110 translation of our platform, including viral biodistribution, editing efficiencies in various organs,

111 Head-to-head biodistribution experiments comparing SA-biotin and bisp

112 Biodistribution experiments showed an accumulation of (1

113 Biodistribution experiments using normal rats were perfo

114 of a label at the C terminus yields the best biodistribution features for both radiometal and radioha

115 vivo imaging data were supported by ex vivo biodistribution, flow cytometry, and immunohistochemistr

116 :(68)Ga-THP-PSMA is safe and has a favorable biodistribution for clinical imaging.

117 Biodistribution in a nonhuman primate showed binding in

118 n quantitatively depict in vivo intrahepatic biodistribution in a rat model.

119 olic fate of (11)C-acetate; then discuss its biodistribution in health and disease; and subsequently

120 Tracer biodistribution in healthy humans showed favorable kinet

121 vity of [(18)F]CFA for dCK and its favorable biodistribution in humans justify further studies to val

122 Pr, metabolic stability in blood plasma, and biodistribution in mice bearing GRPr-expressing PC3 xeno

123 ical trial was to investigate the safety and biodistribution in normal tissues and uptake in tumor le

124 loyed to examine the temporal GSK1265744 LAP biodistribution in rat following either IM or SC adminis

125 Assessment of the biodistribution in rodents of a prototypical Alexa647-la

126 beta6 integrin expression by PET and ex vivo biodistribution in severe combined immunodeficiency mice

127 (68)Ga-PSMA-11 and (68)Ga-RM2 had distinct biodistributions in this small cohort of patients with b

128 ging agents, and characterizing nanoparticle biodistribution is essential for evaluating their effica

129 ons (i.e. the bioavailability and subsequent biodistribution) is mostly unknown.

130 In parallel, biodistribution, kinetics of the lesions, and radiation

131 Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of (6

132 patients with metastatic colorectal cancer, biodistribution (liver, lung) and liver-lung shunt (LLS)

133 PET/CT imaging and ex vivo biodistribution measurement were conducted on BALB/c mic

134 , using dual-energy SPECT imaging and tissue biodistribution measurements.

135 Purpose To evaluate the biodistribution, metabolism, and pharmacokinetics of a n

136 counting, and flow cytometry to evaluate the biodistribution, nanomedicines' uptake by plaque-associa

137 Biodistribution of (11)C-GSK1482160 in saline- and lipop

138 non-Hodgkin lymphoma (NHL) and compared the biodistribution of (11)C-MET PET/CT with that of (18)F-F

139 e first study, human radiation dosimetry and biodistribution of (11)C-metformin were estimated in 4 s

140 The biodistribution of (125)I-iodo-DPA-713 was determined un

141 The tumor and normal tissue biodistribution of (177)Lu-DOTA-Fab-PEG24-EGF was studie

142 ith respect to the available literature, the biodistribution of (18)F-FAZA in humans appeared to be s

143 The biodistribution of (213)Bi-IMP288 was comparable to that

144 The biodistribution of (64)CuCl2 is more suitable than that

145 r theranostic application by determining the biodistribution of (68)Ga-NeoBOMB1 and (177)Lu-NeoBOMB1.

146 s phase 1 study was to assess the safety and biodistribution of (68)Ga-THP-PSMA.

147 The biodistribution of (89)Zr-bevacizumab was quantified as

148 As a proof of concept, the biodistribution of (89)Zr-Df-pembrolizumab was further i

149 Dose-dependent biodistribution of (89)Zr-MSB0010853 was assessed ex viv

150 By measuring the biodistribution of 30 nanoparticles to eight tissues sim

151 Additionally, the biodistribution of [(18)F]FPTMP in a nonhuman primate sh

152 Biodistribution of [Lys(40)(NODAGA-(68)Ga)NH2]Ex(9-39) s

153 Biodistribution of [Nle(14),Lys(40)(Ahx-DOTA-(68)Ga)NH2]

154 The biodistribution of adenovirus type 5 (Ad5) vector partic

155 In vivo biodistribution of anti-CD47-QD was assessed with induct

156 FMT/CT imaging allows quantifying the biodistribution of antibodies in nude mice and provides

157 to PET/MRI for quantitative analysis of the biodistribution of different antibody formats and depend

158 Metabolism and biodistribution of EDHB were analyzed using liquid chrom

159 Metabolism and biodistribution of EDHB were analyzed using liquid chrom

160 The affinity and biodistribution of Ex(9-39)NH2-based antagonists, modifi

161 lts that take into account both the measured biodistribution of gold nanoparticles at the cellular le

162 y be used in patients to help understand the biodistribution of GSK1265744 LAP and its associated pha

163 resonance (NMR) 'cytometry' to quantify the biodistribution of immunotherapeutic T cells in intact t

164 sizes to bone and is untreatable due to poor biodistribution of intravenously administered anticancer

165 Whilst the biodistribution of LNCs of different size has been studi

166 loped a method to simultaneously measure the biodistribution of many chemically distinct nanoparticle

167 Time-dependent biodistribution of MSB0010853 was analyzed ex vivo at 3,

168 Biodistribution of polyplexes in a murine asthmatic mode

169 though in some mice we detected extravesical biodistribution of QD suggesting a route for systemic ex

170 Here, we explored the in vivo biodistribution of radiolabeled asparaginase, using a co

171 ur understanding of the pharmacokinetics and biodistribution of radiolabeled pembrolizumab in vivo, w

172 In vivo biodistribution of radiolabeled targeted Pam-NPs demonst

173 ing in a hemophilia A patient and assess the biodistribution of the cells after intravenous injection

174 -mortem Pt determination in the tissues, the biodistribution of the drug nanocarriers was also monito

175 PEG-Asc NPs resulted in significantly higher biodistribution of the drug to the brain than other form

176 Finally, the biodistribution of the dual-labeled tracer was determine

177 neously investigate the pharmacokinetics and biodistribution of the polymer carrier and drug EPI.

178 This includes physiologic biodistribution of the radiotracer, as well as condition

179 nd can drastically modify the life cycle and biodistribution of the whole heterostructure.

180 dings challenge current understanding of the biodistribution of these contrast agents and their safet

181 We present pilot data on the biodistribution of these PET tracers in a small cohort o

182 In order to assess the biodistribution of this peptide, it was conjugated with

183 Results from the in vivo biodistribution of UCNPs@mSiO2, cellular live/dead assay

184 (18)F-FLT biodistribution over time revealed a previously unknown

185 hese selected modifications harnessed innate biodistribution pathways through the structure-inherent

186 estigated this hypothesis by correlating the biodistribution pattern and the adjuvanticity of the str

187 A consistent biodistribution pattern was observed with low background

188 ds exhibit absorption, pharmacokinetics, and biodistribution patterns that are significantly altered

189 target specific cellular uptake mechanisms, biodistribution patterns, and pharmacokinetics.

190 combined immunodeficient mice were used for biodistribution, PET imaging, and determination of in vi

191 PET/CT-based biodistribution, pharmacokinetics, and radiation dosimet

192 Materials and Methods Biodistribution, pharmacokinetics, and stability of CM-1

193 identical LbL coatings with regard to their biodistribution, pharmacokinetics, and toxicities.

194 and examine the impact by surface coating on biodistribution, pharmacokinetics, and tumor retention.

195 Biodistribution, pharmacokinetics, SPECT/CT, and dosimet

196 On the basis of the superior biodistribution profile compared with previously reporte

197 Given the favorable biodistribution profile of (99m)Tc- and (111)In-labeled

198 clinical trials, due to a slightly superior biodistribution profile, less myelosuppression, and supe

199 Biodistribution profiles and both nuclear and optical in

200 Complexes 13 and 13* exhibited comparable biodistribution profiles with both hepatic and renal exc

201 -C2Am and (111)In-C2Am also showed favorable biodistribution profiles, with predominantly renal clear

202 n vivo, it is critical to characterize their biodistribution profiles.

203 study was to quantitatively investigate the biodistribution properties of said ligand and understand

204 To assess its biodistribution properties, SPECT and CT scans of HT29-x

205 Safety, biodistribution, radiation dosimetry, and the most appro

206 Similarly, ex vivo biodistribution results revealed notably higher (64)Cu-r

207 Biodistribution revealed high tumor uptake of all agents

208 Whole-body biodistribution revealed that the liver and the brain ar

209 e we describe preclinical tumorigenicity and biodistribution safety studies that were required by the

210 Peptide biodistribution showed high tumor uptake by comparison w

211 The biodistribution showed increased accumulation in the liv

212 Biodistribution showed low tissue gadolinium levels at 2

213 Ex vivo biodistribution showed protein dose- and time-dependent

214 Biodistribution showed uptake of (211)At- 6: in PSMA+ PC

215 e from most organs and blood was quick, with biodistribution showing prominent kidney retention, low

216 (111)In-OPS201 had a biodistribution significantly different from (90)Y-OPS20

217 (18)F-TFB shows a biodistribution similar to (99m)Tc-pertechnetate, a know

218 )Cu-NOTA-PEG4-cRGD2 demonstrated a favorable biodistribution, slow washout, and excellent performance

219 ising target-to-background ratios in ex vivo biodistribution studies (12.3 and 15.2 tumor-to-muscle r

220 ntagonist than of the agonist as measured in biodistribution studies 285 min after radiotracer inject

221 opic breast tumors for in vivo SPECT/MRI and biodistribution studies after injection with (177)Lu-DOT

222 Ex vivo biodistribution studies confirmed a high and persistent

223 .001) than (18)F-FDG through PET imaging and biodistribution studies in MDA-MB-231 and MDA-MB-157 xen

224 rget CA125 and evaluated via PET imaging and biodistribution studies in mice bearing OVCAR3 human ova

225 Biodistribution studies in mice indicated that ARC-520 g

226 In vivo PET imaging and ex vivo biodistribution studies in mice with breast, lung, and e

227 and subsequently in vivo by PET and ex vivo biodistribution studies in mice xenografted with breast

228 1)C-methyl-taurine-conjugated bile acids and biodistribution studies in pigs by PET/CT.

229 In vivo biocompatibility and organ biodistribution studies of L-N-BPs were undertaken simul

230 Biodistribution studies of the iodine-125 analogue showe

231 (177)Lu-NeoBOMB1 biodistribution studies revealed a higher tumor uptake (

232 Biodistribution studies revealed accretion of (89)Zr-DFO

233 d in vivo proteasome inhibition analysis and biodistribution studies revealed decreased toxicity and

234 Biodistribution studies revealed increased transferrin-b

235 Biodistribution studies revealed tissue alendronate conc

236 Results from biodistribution studies show a rapid and high uptake of

237 Importantly, biodistribution studies show that these compounds exhibi

238 In vivo imaging and biodistribution studies showed a rapid accumulation of a

239 PET imaging and biodistribution studies showed fast clearance from blood

240 Mouse biodistribution studies showed moderate initial brain up

241 Biodistribution studies showed similar distribution of (

242 PET imaging and biodistribution studies showed that injecting the radiol

243 eveloped and used in preclinical imaging and biodistribution studies to assess their ability to detec

244 Biodistribution studies using HT29 tumor-bearing mice sh

245 Data obtained from PET scans and biodistribution studies were extrapolated to humans to e

246 Post-SPECT biodistribution studies were performed 96 h after inject

247 Small animal PET and biodistribution studies were performed in both B16F10 an

248 In vivo PET imaging and ex vivo biodistribution studies were performed in mice bearing x

249 Ex vivo biodistribution studies were performed in mice.

250 PET imaging and biodistribution studies were performed in nude mice bear

251 Also, biodistribution studies were performed in tumor-xenograf

252 el ((18)F/(125)I) internalization assays and biodistribution studies were performed on HER2-expressin

253 Whole-animal biodistribution studies were performed on saline- or lip

254 Murine biodistribution studies were performed to support human

255 In vivo metabolite analyses and biodistribution studies were performed using CD-1 nu/nu

256 Results of the biodistribution studies were used to determine pharmacok

257 PET imaging and ex vivo biodistribution studies with (18)F-FHNP and (18)F-FES we

258 Biodistribution studies with radiolabeled CAF09 and a su

259 (CD30-negative model) using PET/CT imaging, biodistribution studies, and autoradiography.

260 Biodistribution studies, autoradiography, and PET experi

261 In biodistribution studies, highest PDE5-specific retention

262 d and [(11)C]11e through autoradiography and biodistribution studies, imaging of neither [(124)I]11d

263 (18)F-FDG, as shown through PET imaging and biodistribution studies.

264 o BC mouse model and performed SPECT/MRI and biodistribution studies.

265 ificity in ex vivo autoradiography and brain biodistribution studies.

266 I and evaluated by SPECT imaging and ex vivo biodistribution studies.

267 the metal content in the animal tissues for biodistribution studies.

268 ce by both small-animal SPECT/CT and ex vivo biodistribution studies.

269 The biodistribution study for patients treated with (177)Lu-

270 ocalization to shoulder and knee joints in a biodistribution study in normal mice.

271 A biodistribution study showed effective tumor-targeting b

272 The rat biodistribution study showed that (11)C-JNJ-54173717 cro

273 ith respect to binding, internalization, and biodistribution through a rational design of correspondi

274 roach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site.

275 Biodistribution to lungs, stomach-intestine, liver, trac

276 anding of how nanoparticle structure affects biodistribution to off-target organs.

277 n nanoparticle (ZNP) uptake by the roots and biodistribution to the leaves of soybean plants was meas

278 particles (AuNPs) were used to determine the biodistribution, toxickinetic, and genotoxicity variance

279 pid and quantitative method to evaluate cell biodistribution, tumor homing, and fate in preclinical s

280 To investigate in vivo biodistribution, two differently modified alphaCD20 anti

281 Importantly, our results demonstrate that Se biodistribution varies significantly throughout developm

282 Biodistribution was analyzed for 11 organs using MIM sof

283 Biodistribution was consistent with a major elimination

284 Biodistribution was determined in mice bearing PSMA+ PC3

285 % and 98-100% respectively, and the liposome biodistribution was imaged by PET for up to 8days.

286 effect of lipophilicity and structure on the biodistribution was investigated in pigs by PET/CT using

287 (18)F-FDG biodistribution was measured for comparison.

288 Methods:(18)F-FLT biodistribution was measured in 3 strains of male and fe

289 Ex vivo biodistribution was performed after the last imaging ses

290 I-29-41 was administrated intravenously, and biodistribution was performed at 30, 60, and 120 min.

291 Biodistribution was performed by injecting a (67)Ga-, (1

292 Dox biodistribution was quantified and compared with that of

293 gamma spectroscopy, and temporal changes in biodistribution were assessed using autoradiography.

294 Tracer blood kinetics and biodistribution were compared with (99m)Tc-RP805 in C57B

295 binding affinity, in vivo tumor uptake, and biodistribution were compared with the GRPr antagonists

296 HER2-targeting properties and biodistribution were evaluated in BALB/C nu/nu mice bear

297 PET imaging and biodistribution were performed 24 h after administration

298 d on pharmacokinetic modeling of radiotracer biodistribution, which requires the blood input function

299 By tracking in vivo nanoparticle biodistribution with MSOT, it was shown that pH responsi

300 However, maps of the PpIX biodistribution within the surgical field based on eithe